# UARK 2014-14: Phase II Prospective Evaluation of Bone Remodeling During Ixazomib Treatment

> **NCT02499081** · PHASE2 · COMPLETED · sponsor: **University of Arkansas** · enrollment: 20 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Ixazomib

## Key facts

- **NCT ID:** NCT02499081
- **Lead sponsor:** University of Arkansas
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-09
- **Primary completion:** 2018-05-17
- **Final completion:** 2018-05-17
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2021-06-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02499081

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02499081, "UARK 2014-14: Phase II Prospective Evaluation of Bone Remodeling During Ixazomib Treatment". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02499081. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*